Results 61 to 70 of about 4,832 (178)

Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial

Journal of Asthma and Allergy, 2018
Pamela L Zeitlin,1 Mila Leong,2 Jeremy Cole,3 Raburn M Mallory,4 Vivian H Shih,5 Richard F Olsson,6 Mitchell Goldman5 On behalf of the ALIZE study investigators 1Department of Pediatrics, National Jewish Health, Denver, CO, USA; 2Pediatric Pulmonary and ...
Zeitlin PL, Leong M, Cole J, Mallory RM, Shih VH, Olsson RF, Goldman M   +6 more
doaj  

Immune checkpoint inhibitor‐induced eosinophilic fasciitis: A pharmacovigilance and EADV Task force study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
A comprehensive retrospective analysis of 121 immune checkpoint inhibitor‐induced eosinophilic fasciitis cases, including clinical presentation, diagnostic features and treatment outcomes using data from the EADV Task Force ‘Dermatology for Cancer Patients’, two international pharmacovigilance databases and the current literature.
Tristan V. M. Bruijn, Alexandre O. Gérard, Maëlys Labat, Zoe Apalla, Wouter van Binsbergen, Dimitra Koumaki, Valerian Rivet, Frederic Dezoteux, Damien Giacchero, Michael R. Ardern‐Jones, Kara Heelan, Jesse P. Hirner, Ander Mayor, Mariette Labots, Markus V. Starink, Conny J. van der Laken, Vincent Sibaud, Yannick S. Elshot   +17 more
wiley   +1 more source

Mepolizumab versus benralizumab for eosinophilic granulomatosis with polyangiitis (EGPA): A European real-life retrospective comparative study [PDF]

Background: Following the results of the MANDARA trial, this real-life study aimed at comparing the effectiveness and safety profile of mepolizumab versus benralizumab in a European EGPA cohort.
Salvarani C, Egan A., Cohen Tervaert J. W., Crimi C., Losappio L, Caminati M, Guarnieri G, Marchi MR, Sinico RA, Mattioli I, Trivioli G, Cinetto F., Moi L, Del Giacco S, Samson M, Treppo E., Marvisi C, Cottin V., Kernder A., Lo Gullo A., Lombardi C., Desaintjean C., Cameli P., Bianchi F. C., Marchi M. R., Hellmich B, Emmi G., Urban ML, Cohen Tervaert JW, Mohammad AJ, Egan A, Rivera CM, Folci M, Seeliger B, Franceschini F., Maule M, Guarnieri G., Groh M., Maule M., Nolasco S., Samson M., Fornaro M., Vaglio A., Roccatello D., Fornaro M, Vacca A., Tcherakian C., Caminati M., Cottin V, Roccatello D, Vaglio A, Negrini SM, Berti A, Berti A., Emmi G, Seeliger B., Neumann T., Moroncini G, Govoni M., Solans R, Padoan R., Vacca A, Moi L., Coppola A, Treppo E, Monti S., Novikov P, Espigol-Frigole G., Bettiol A., Desaintjean C, Bianchi FC, Moosig F, Marvisi C., Nolasco S, Govoni M, Cinetto F, Salvarani C., Jones R., Schroeder J. W., Costanzo G., Sinico R. A., Trivioli G., Hellmich B., Iannone F., Novikov P., Franceschini F, Kernder A, Mohammad A. J., Toniati P., Schroeder JW, Negrini S. M., Tcherakian C, Cathébras P, Monti S, Solans R., Moosig F., Jayne D., Crimi C, Jones R, Coppola A., Lo Gullo A, Lopalco G., Mattioli I., Toniati P, Iannone F, European EGPA Study Group., Bettiol A, Moroncini G., Costanzo G, Del Giacco S., Baldini C, Baldini C., Lombardi C, Losappio L., Folci M., Cameli P, Cathebras P., Urban M. L., Padoan R, Neumann T, Jayne D, Groh M, Espigol-Frigolé G, Lopalco G, Rivera C. M.   +124 more
core   +4 more sources

Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma

Journal of Asthma and Allergy, 2022
Saad AlShareef,1 Christine F McDonald,2– 4 Joy Lee2,5 1Department of Medicine, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, 13317-4233, Saudi Arabia; 2Department of Respiratory and Sleep Medicine, Austin Health ...
AlShareef S, McDonald CF, Lee J
doaj  

Financial Toxicity Associated with Biological Medicines: A Scoping Review

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 81-93, July 2026.
Financial toxicity, defined as the economic burden experienced by patients due to medication and other healthcare costs and their consequences, such as material, psychosocial and behavioral effects, represents a significant concern for individuals receiving biological medicines.
Laura Sara Maria Saarukka, Kamilla Yamileva, Kari Linden, Anniina Simonen, Anna‐Riia Holmström   +4 more
wiley   +1 more source

Benralizumab: Der IL-5-Rezeptor als Ziel bei schwerem eosinophilem Asthma

, 2019
Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma For patients with difficult-to-control, severe bronchial asthma, highly effective, targeted treatment options are available in addition to inhaled medication.
Thomas Rothe, Solèr, Markus, Schmid-Grendelmeier, Peter, Peter Schmid-Grendelmeier, Gunther Pendl, von Garnier, Christophe, Simon, Hans-Uwe, Christophe von Garnier, Hans-Uwe Simon, Claudio Schuoler, Jörg D. Leuppi, Rothe, Thomas, Pendl, Gunther, Markus Solèr, Leuppi, Jörg D, Schuoler, Claudio   +15 more
core   +1 more source

Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma

, 2019
International audienceObjective: Treatment with benralizumab significantly reduces exacerbations and improves lung function after 1 year and decreases oral corticosteroid (OCS) use after 28 weeks for patients with severe, uncontrolled eosinophilic asthma.
Bourdin, Arnaud, Brooks, Laura, Garcia Gil, Esther, FitzGerald, J Mark, Bleecker, Eugene, R., Busse, William, Shaw, Dominick, Ferguson, Gary, Barker, Peter, Menzies-Gow, Andrew, Martin, Ubaldo, Bleecker, Eugene,   +11 more
core   +2 more sources

Coexisting Asthma and Diabetes Are Associated With Adverse Metabolic and Inflammatory Profiles

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 6073-6085, July 2026.
ABSTRACT Aims Asthma and diabetes frequently co‐occur and share metabolic and inflammatory features, yet the cardiometabolic profile associated with their coexistence is not well defined. We examined differences in cardiometabolic and inflammatory biomarkers by joint asthma–diabetes status in U.S.
Sixtus Aguree, Patricia Silveyra, Nianjun Liu, Arthur H. Owora, Tesfaye B. Mersha   +4 more
wiley   +1 more source

Differential Effects of Benralizumab and Mepolizumab on Pro‐Resolving Mediators

Allergy, EarlyView.
Jaime Bernaola, José Antonio Cañas, Álvaro Arranz‐Fragua, José Manuel Rodrigo‐Muñoz, Daniel Rodríguez‐González, Antonio Serrano‐Santiago, Gema Guillén‐Sánchez, Alma Martínez Fernández, Marcela Valverde‐Monge, Diana Betancor, Erwin Javier Pinillos‐Robles, Claudia Rodríguez‐Busto, María Jesús Rodríguez‐Nieto, Joaquín Sastre, Victoria del Pozo   +14 more
wiley   +1 more source

Interleukin‐5, Eosinophils, and Interleukin‐5 Pathway Inhibitors in Eosinophilic Granulomatosis With Polyangiitis

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1196-1205, June 2026.
Interlukin‐5 (IL‐5) plays a crucial role in the pathogenesis of eosinophilic granulomatosis with polyangiitis (EGPA) by promoting eosinophil differentiation, activation, and survival. We present here a typical case of EGPA in which treatment with IL‐5 pathway inhibitors is prescribed, showing to be beneficial for the patient.
Alvise Berti, Christian Pagnoux
wiley   +1 more source